Synovia (Undenatured type II collagen)

Synovia is a patented form of undenatured type II collagen (UC-II) derived from chicken sternum cartilage, containing intact triple-helix collagen peptides and chondroitin sulfate. It works primarily through oral tolerance, where small doses interact with gut-associated lymphoid tissue (GALT) to suppress autoimmune-like cartilage degradation rather than serving as a structural building block.

Origin & History

Synovia (undenatured type II collagen) is a branded form of native collagen derived from chicken sternum or breast cartilage, processed at low temperatures (≤50°C) to preserve its three-dimensional structure and active epitopes. Production involves pulverizing cartilage, defatting with NaOH and ethanol, acid treatment, enzymatic hydrolysis (using pepsin or elastase), and drying to yield a water-soluble powder with approximately 3.9% collagen content.

Historical & Cultural Context

No historical or traditional medicinal use is documented for undenatured type II collagen in the research. It is a modern, patented nutraceutical ingredient developed through low-temperature extraction technology specifically for joint health applications.

Health Benefits

• Reduces knee osteoarthritis pain - RCT (n=191) showed significant WOMAC pain score reduction (p=0.002) after 180 days
• Improves joint stiffness - Clinical trial demonstrated significant reduction in WOMAC stiffness scores (p=0.002)
• Enhanced physical function - Significant improvement in WOMAC physical function scores (p<0.001) in controlled study
• Decreases overall pain levels - VAS pain scores significantly reduced (p=0.001) in knee OA patients
• Reduces rescue medication use - Clinical evidence shows decreased need for pain relief medications

How It Works

Synovia's undenatured type II collagen is processed in Peyer's patches of the small intestine, where it interacts with regulatory T-cells (Tregs) to induce peripheral tolerance to native cartilage collagen, suppressing pro-inflammatory cytokines such as TNF-α and IL-1β that drive chondrocyte degradation. This oral tolerization mechanism downregulates matrix metalloproteinases (MMP-1, MMP-3, MMP-13), which are enzymes responsible for extracellular matrix breakdown in articular cartilage. Unlike hydrolyzed collagen, the intact triple-helix conformation is essential for this immunomodulatory effect, as denaturation abolishes receptor recognition at the gut mucosal level.

Scientific Research

A randomized, double-blind, placebo-controlled trial (n=191 patients with knee OA, PMID: 26817870) tested 40 mg/day UC-II for 180 days, demonstrating significant improvements in WOMAC pain, stiffness, and physical function scores compared to placebo. Multiple reviews confirm UC-II benefits for OA symptoms, with novel ELISA assays validating joint health effects from chicken sternum cartilage.

Clinical Summary

A randomized controlled trial (n=191) over 180 days demonstrated that Synovia supplementation produced statistically significant reductions in WOMAC pain scores (p=0.002) and WOMAC stiffness scores (p=0.002) compared to placebo in patients with knee osteoarthritis. Physical function sub-scores on the WOMAC scale also showed significant improvement, suggesting broad symptomatic benefit beyond isolated pain relief. Evidence is primarily supported by industry-funded RCT data at this stage, and while results are promising, independent large-scale replication would strengthen the evidence base. Effective doses in trials have generally ranged from 40–80 mg per day of undenatured type II collagen, substantially lower than the gram-level doses used with hydrolyzed collagen.

Nutritional Profile

Synovia (Undenatured Type II Collagen) is a highly purified, native collagen extract derived primarily from chicken sternum cartilage, standardized to contain a minimum of 25-40% undenatured (native) type II collagen per serving. Typical clinical doses are 40mg/day of undenatured type II collagen. Key bioactive components include: native triple-helix collagen peptide chains (preserved in non-denatured form, critical for oral tolerance mechanism via Peyer's patches in the gut), chondroitin sulfate (approximately 5-15% by weight in raw extract), hyaluronic acid (trace amounts, typically <1%), and glucosamine (minor residual amounts). Protein content constitutes the majority of the supplement's mass (~60-70% protein by dry weight), composed primarily of alpha-1 and alpha-2 collagen chains rich in hydroxyproline, hydroxylysine, glycine (~33% of amino acid composition), and proline (~13%). Micronutrient content is minimal and not clinically significant. Bioavailability note: Unlike hydrolyzed collagen, undenatured type II collagen works via immune-modulated oral tolerance rather than direct tissue incorporation — the intact triple-helix structure must remain preserved for biological activity, meaning it should not be denatured by heat or harsh processing. Absorption of the intact molecule is not required; interaction with gut-associated lymphoid tissue (GALT) at low doses (40mg) is the proposed mechanism of action.

Preparation & Dosage

The clinically studied dose for undenatured type II collagen powder is 40 mg once daily, taken in the evening without food. This standardized dose targets the native, undenatured form with intact epitopes, typically containing 3.9% active collagen verified by ELISA. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Glucosamine, Chondroitin, MSM, Boswellia, Turmeric

Safety & Interactions

Synovia is generally well-tolerated in clinical trials, with adverse event profiles comparable to placebo at studied doses of 40–80 mg/day. Individuals with poultry or egg allergies should exercise caution, as the collagen is chicken-derived and allergic reactions, though rare, are plausible. No clinically significant drug interactions have been formally documented, but theoretical interactions with immunosuppressant medications (e.g., methotrexate, corticosteroids) exist given its immunomodulatory mechanism via Treg pathways. Safety data in pregnant or breastfeeding women are insufficient, and use during pregnancy is not recommended without medical supervision.